Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 20/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24460275 | 0.95 | FYN (0.48) | FYN | |
| SCHEMBL19781269 | 0.90 | FYN (0.58) | FYN | |
| SCHEMBL24460469 | 0.85 | FYN (0.53) | FYN | |
| SCHEMBL24460283 | 0.82 | FYN (0.50) | FYN | |
| SCHEMBL24460284 | 0.82 | FYN (0.61) | FYN | |
| SCHEMBL24460282 | 0.80 | FYN (0.63) | FYN | |
| SCHEMBL19781146 | 0.78 | PIK3CA (0.44) | FYN | |
| SCHEMBL19781794 | 0.76 | DYRK1A (0.58) | FYN | |
| SCHEMBL26361838 | 0.76 | FYN (0.49) | FYN | |
| SCHEMBL19781134 | 0.76 | CLK1 (0.43) | FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2022108849-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | C3AR1, C9, C1R | FYN 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.